← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Traditional approvalTraditional conversionMedullary thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients aged 2 years and older with advanced or metastatic medullary thyroid cancer, an FDA test-confirmed RET mutation and a need for systemic therapy.

LAMPGEN ANALYSIS

Why it matters

This traditional approval confirmed the medullary thyroid cancer indication after a randomized comparison against standard kinase inhibitors.

What research teams should watch

Record the exact RET alteration and age, and track what evidence comes from the adult/adolescent trial versus the pediatric data.

PRIMARY RECORDS

Sources